.png)
ORLANDO, Fla. — The topical Janus tyrosine kinase (JAK) 1/2 inhibitor ruxolitinib improved itching and nodules in patients with prurigo nodularis (PN) significantly better than a vehicle within a week after starting therapy, with improvements continuing out to 3 months, in a global phase 3 clinical trial...
Axis Mundi Systems LLC 3773 Howard Ave Las Vegas, NV
Toll Free: 877-749-7128 ext. 500
office@cruisewithbruce.com
Copyright © 2023 virtualluxurytravelnews. All Rights Reserved
